Bharat Immunologicals Price to Book vs. Cash and Equivalents

BIBCL -- India Stock  

INR 20.40  1.55  8.22%

The Drivers Module shows relationships between Bharat Immunologicals's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Bharat Immunologicals Biologicals Corp Ltd over time as well as its relative position and ranking within its peers. Check also Trending Equities

Bharat Immunologicals Cash and Equivalents vs. Price to Book Fundamental Analysis

Bharat Immunologicals Biologicals Corp Ltd is rated below average in price to book category among related companies. It is rated below average in cash and equivalents category among related companies creating about  90,388,462  of Cash and Equivalents per Price to Book.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.
Bharat Immunologicals 
P/B 
 = 
MV Per Share 
BV Per Share 
=
2.60 times
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Bharat Immunologicals 
Cash 
 = 
Bank Deposits 
+  
Liquidities 
=
235.01 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually 3 months).

Bharat Immunologicals Cash and Equivalents Comparison

Bharat Immunologicals is currently under evaluation in cash and equivalents category among related companies.
Bharat Immunologicals is currently under evaluation in price to book category among related companies.